Latest Period
Q2 2026
Security Snapshot
Apogee Therapeutics, Inc. - Common Stock (APGE) Institutional Ownership
CUSIP: 03770N101
13F Institutional Holders and Ownership History from Q3 2023 to Q2 2026
Institutions Reporting
288
Shares (Excl. Options)
67,571,293
Price
$132.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- APGE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 67,571,293
- Total 13F value
- $8,928,070,300
- Portfolio coverage rank
- 0.02%
- Share change
- -10,323,508
- Value change
- -$1,003,136,187
- Number of holders
- 288
- Shares outstanding
- 62,702,889
- SEC-reported price per share
- $134.20
- Insider filing price
- $134.20
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- APGE - Apogee Therapeutics, Inc. - Common Stock is tracked under CUSIP 03770N101.
- 288 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 222 to 288 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $6,638,906,729 to $8,928,070,300.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 288 institutions filings for Q2 2026.
Security key
03770N101
Latest holder period
Q2 2026
13F holders
288
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
APGE full holder history
Apogee Therapeutics, Inc. SEC filings
Apogee Therapeutics, Inc. company facts
Apogee Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03770N101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
APGE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 10% | 0% | $529,859,960 | +$3,409,683 | 6,808,789 | +0.65% | Peter Evan Harwin | 18 Jun 2026 |
| RTW INVESTMENTS, LP | 4.9% | -18% | $214,255,663 | 2,712,097 | 0% | RTW Investments, LP | 31 Dec 2025 | |
| BlackRock, Inc. | 5.5% | $109,396,539 | 2,518,725 | BlackRock, Inc. | 30 Jun 2025 | |||
| FMR LLC | 4% | -73% | $330,912,044 | -$585,861,778 | 2,493,137 | -64% | FMR LLC | 30 Jun 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4.7% | $85,757,284 | 2,158,502 | DRIEHAUS CAPITAL MANAGEMENT LLC | 30 Sep 2025 | |||
| T. Rowe Price Investment Management, Inc. | 1.3% | -91% | $102,595,557 | -$1,263,349,841 | 772,969 | -92% | T. Rowe Price Investment Management, Inc. | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.9% | -87% | $74,902,539 | -$555,107,891 | 564,326 | -88% | Wellington Management Group LLP | 30 Jun 2026 |
As of 30 Jun 2026, 288 institutional investors reported holding 67,571,293 shares of Apogee Therapeutics, Inc. - Common Stock (APGE). This represents 108% of the company’s total 62,702,889 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 14% | 8,493,321 | 0% | 34% | $1,127,318,496 |
| BlackRock, Inc. | 8.8% | 5,507,032 | +35% | 0.01% | $730,948,292 |
| HBK INVESTMENTS L P | 4.5% | 2,850,000 | 4.4% | $378,280,500 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 2,572,119 | +2.8% | 0.01% | $341,397,355 |
| FMR LLC | 4% | 2,493,137 | -73% | 0.01% | $330,914,038 |
| STATE STREET CORP | 3.7% | 2,297,743 | +6.2% | 0.01% | $304,979,428 |
| Driehaus Capital Management LLC | 2.8% | 1,740,101 | -9.4% | 1.3% | $230,963,606 |
| GOLDMAN SACHS GROUP INC | 2.7% | 1,693,341 | +159% | 0.02% | $224,757,151 |
| Balyasny Asset Management L.P. | 2.7% | 1,665,102 | +280% | 0.4% | $221,008,988 |
| GLAZER CAPITAL, LLC | 2.6% | 1,641,042 | 5.4% | $217,816,000 | |
| Paradigm Biocapital Advisors LP | 2.5% | 1,576,385 | +17% | 3.9% | $209,233,581 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4% | 1,528,750 | +286% | 0.01% | $202,910,988 |
| MILLENNIUM MANAGEMENT LLC | 2.4% | 1,491,404 | +1511% | 0.13% | $197,954,053 |
| Pentwater Capital Management LP | 2.3% | 1,425,000 | 1.5% | $189,140,250 | |
| MORGAN STANLEY | 2.3% | 1,421,681 | +139% | 0.01% | $188,699,836 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,314,868 | +8% | 0.01% | $174,560,515 |
| PERCEPTIVE ADVISORS LLC | 2.1% | 1,308,113 | -15% | 2.7% | $173,625,838 |
| Jupiter Topco LLC | 1.9% | 1,193,626 | 0% | 0.06% | $158,402,405 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 1,126,139 | +25% | 0.01% | $149,472,430 |
| Affinity Asset Advisors, LLC | 1.6% | 987,000 | -23% | 6.4% | $131,004,510 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.5% | 941,283 | +13% | 0.15% | $124,936,493 |
| First Light Asset Management, LLC | 1.5% | 930,289 | +61% | 7.5% | $123,477,259 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 775,058 | -22% | 0.02% | $65,236,632 |
| T. Rowe Price Investment Management, Inc. | 1.2% | 762,183 | -93% | 0.07% | $101,165,000 |
| Kryger Capital LLC | 1.2% | 742,555 | 5.6% | $98,559,325 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q2 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 67,571,293 | $8,928,070,300 | -$1,003,136,187 | $132.73 | 288 |
| 2026 Q1 | 79,061,115 | $6,638,906,729 | +$743,266,174 | $84.17 | 222 |
| 2025 Q4 | 69,771,331 | $5,266,434,045 | +$762,006,154 | $75.48 | 206 |
| 2025 Q3 | 59,584,020 | $2,367,665,644 | +$56,487,603 | $39.73 | 173 |
| 2025 Q2 | 57,837,483 | $2,511,890,310 | -$147,322,983 | $43.43 | 180 |
| 2025 Q1 | 61,488,037 | $2,301,755,351 | +$131,273,115 | $37.36 | 165 |
| 2024 Q4 | 57,873,775 | $2,621,627,227 | +$63,332,544 | $45.30 | 156 |
| 2024 Q3 | 56,092,373 | $3,292,239,932 | +$134,148,823 | $58.74 | 137 |
| 2024 Q2 | 54,152,101 | $2,130,892,019 | -$9,800,456 | $39.35 | 137 |
| 2024 Q1 | 52,915,146 | $3,516,219,943 | +$778,331,224 | $66.45 | 137 |
| 2023 Q4 | 41,768,396 | $1,163,676,392 | +$48,111,524 | $27.94 | 85 |
| 2023 Q3 | 40,111,211 | $848,653,526 | +$848,653,497 | $21.30 | 73 |